Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models
…, RD Divate, NL Navlani, V Sharma, A Parikh… - Vaccine, 2021 - Elsevier
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), initially originated in
China in year 2019 and spread rapidly across the globe within 5 months, causing over 96 …
China in year 2019 and spread rapidly across the globe within 5 months, causing over 96 …
Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197
…, M Mahajan, T Mehta, AK Singh, A Parikh… - Biosimilars, 2014 - Taylor & Francis
ZRC-3197 has been developed indigenously by Cadila Healthcare Ltd as a biosimilar
adalimumab of originator HUMIRA ® . Biosimilarity has been demonstrated with a comprehensive …
adalimumab of originator HUMIRA ® . Biosimilarity has been demonstrated with a comprehensive …
[HTML][HTML] ZRC3308 monoclonal antibody cocktail shows protective efficacy in Syrian hamsters against SARS-CoV-2 infection
…, A Shete, S Bandyopadhyay, S Kumar, A Parikh… - Viruses, 2021 - mdpi.com
We have developed a monoclonal antibody (mAb) cocktail (ZRC-3308) comprising of
ZRC3308-A7 and ZRC3308-B10 in the ratio 1:1 for COVID-19 treatment. The mAbs were designed …
ZRC3308-A7 and ZRC3308-B10 in the ratio 1:1 for COVID-19 treatment. The mAbs were designed …
Immunogenic Potential of DNA Vaccine candidate, ZyCoV-D against SARS-CoV-2 in Animal Models (preprint)
…, RD Divate, NL Navlani, V Sharma, A Parikh… - 2021 - pesquisa.bvsalud.org
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), initially originated in
China in year 2019 and spread rapidly across the globe within 5 months, causing over 96 …
China in year 2019 and spread rapidly across the globe within 5 months, causing over 96 …
ZRC3308 monoclonal antibody cocktail shows protective efficacy in Syrian hamsters against SARS-CoV-2 infection (preprint)
…, A Shete, S Bandhyopadhyay, S Kumar, A Parikh… - 2021 - pesquisa.bvsalud.org
We have developed a monoclonal antibody (mAb) cocktail (ZRC-3308) comprising of
ZRC3308-A7 and ZRC3308-B10 in the ratio 11 for COVID-19 treatment. The mAbs were designed …
ZRC3308-A7 and ZRC3308-B10 in the ratio 11 for COVID-19 treatment. The mAbs were designed …
A novel SARS-CoV-2 related coronavirus in bats from Cambodia (preprint)
…, T Goldstein, E Simon-Loriere, V Duong, A Parikh… - 2021 - pesquisa.bvsalud.org
ABSTRACT Knowledge of the origin and reservoir of the coronavirus responsible for the
ongoing COVID-19 pandemic is still fragmentary. To date, the closest relatives to SARS-CoV-2 …
ongoing COVID-19 pandemic is still fragmentary. To date, the closest relatives to SARS-CoV-2 …
Variant and mutation analysis of SARS-CoV-2 genomes isolated from the Kingdom of Bahrain (preprint)
…, T Goldstein, E Simon-Loriere, V Duong, A Parikh… - 2021 - pesquisa.bvsalud.org
… Khalid M bindayna; Abdel Halim Deifalla; Hicham Ezzat Mohammed Mokbel; Alexandre
Hassanin; Putita Ou Tey; Artem Baidaliuk; Fabiana Gambaro; Vuong Tan Tu; Lucy Keatts; …
Hassanin; Putita Ou Tey; Artem Baidaliuk; Fabiana Gambaro; Vuong Tan Tu; Lucy Keatts; …
[HTML][HTML] Comparison of pathological response of standard chemoradiotherapy versus short course radiotherapy in rectal carcinoma: A pilot study
…, A Shah, A Gami, J Gandhi, A Parikh… - Indian Journal of …, 2023 - journals.lww.com
Objectives: A) Evaluate the morphological changes and pathological response between
SCRT and CRT. B) Compare the pathologic response with outcome between SCRT and CRT. …
SCRT and CRT. B) Compare the pathologic response with outcome between SCRT and CRT. …
Outcomes of MR-guided stereotactic body radiotherapy (SBRT) or yttrium-90 transarterial radioembolization for hepatocellular carcinoma treated at an urban liver …
…, C Burmeister, PJ Massa, J Dragovic, PJ Parikh - 2021 - scholarlycommons.henryford.com
Background: There are overlapping indications for both stereotactic body radiotherapy (SBRT)
and yttrium-90 (Y90) trans-arterial radioembolization as locoregional treatments for …
and yttrium-90 (Y90) trans-arterial radioembolization as locoregional treatments for …
[HTML][HTML] Acinic Cell Carcinoma of Parotid Gland Presenting as Disseminated Cutaneous and Subcutaneous Metastasis after 20 Years of Initial Presentation
…, K Das, N Agrawal, M Kala, R Khanduri, PM Parikh - ijmpo.org
Acinic cell carcinoma (ACC) is an uncommon variety of salivary gland neoplasms, constituting
about 17% of all salivary gland malignancies. Although ACC is a low-grade tumor, …
about 17% of all salivary gland malignancies. Although ACC is a low-grade tumor, …